medigraphic.com
ISSN 2007-2783 (Print)
Órgano Oficial del Instituto Científico Pfizer

2015, Number 1

<< Back Next >>

Residente 2015; 10 (1)

Importancia de las infecciones en el lupus eritematoso sistémico

Saldaña-Anguiano JM, Bonilla-Lara D, Flores-Chávez A, Contreras-Moreno MG, Saucedo-Ulloa M, Aguirre-Romo A, Casillas-Iglesias I, Chávez-García D, González-López L

Language: Spanish
References: 34
Page: 31-37
PDF size: 214.05 Kb.


ABSTRACT

Infections in SLE (systemic lupus erythematosus) are responsible of 40-50% of the morbility and mortality of this disease. The patients with SLE are more susceptible to the development of infections than non-SLE people. This increased susceptibility obeys to genetic factors, factors inherent to the disease (intrinsic) and the effects of immunosupressant drugs. The risk factors that promote the presentation of SLE co-infection are grouped as follows: 1) clinical features of the patient, 2) genetic factors, and 3) pharmaceutic treatment. The increased morbility of infections in patients with SLE is due mainly to the mechanism of action of the drug used. Up to 37% of the patients treated with ciclophosphamide develop a serious infection, which makes this medication the one with the highest association to infections. Bacterial infections are the most frecuent, and the most common are caused by Staphylococus aureus, Escherichia coli, Klebsiella sp. and Pseudomona sp. The most frecuent locations are the respiratory and urinary systems, and the skin. We reviewed the literature to determine the main risk factors implicated in the development of infections in SLE, as well as the physiopatologic description.


REFERENCES

  1. Enriquez MG. Fisiopatología del lupus eritematoso sistémico. Revista de Medicina e Investigación. 2013; 1 (1): 8-16.

  2. Gómez PJ, Cervera R. Lupus eritematoso sistémico. Medicina & Laboratorio. 2008; 14: 5-6.

  3. Jiménez S, Cervera R, Font J, Ingelmo M. The epidemiology of systemic lupus erythematosus. Clinical Reviews in Allergy & Immunology. 2003; 25: 3-11.

  4. Morales J, Cázares JM, Gámez-Nava JI et al. La atención médica en reumatología en un hospital de segundo nivel de atención. Reumatol Clin. 2005; 1: 87-94.

  5. Gómez-Puerta JA, Cervera R. Lupus eritematoso sistémico. Medicina & Laboratorio. 2008; 14: 211-223.

  6. García RA, Sermeño S. Mortalidad por lupus eritematoso sistémico en un hospital público de El Salvador. Rev Arch Col Med. 2008; 1 (1): 2-5.

  7. Silva CE. Inmunopatogenia del lupus eritematoso sistémico. Parte I: factores predisponentes y eventos iniciales. Rev Chil Reumatol. 2009; 25 (3): 108-113.

  8. Petri M. Infection in systemic lupus erythematosus. Rheum Dis Clinic NA. 1998; 2: 423-456.

  9. Pons-Estel B, Catoggio L, Cardiel M, Soriano E, Gentiletti S, Villa A et al. On behalf of the Grupo Latinoamericano de Estudio del Lupus (GLADEL). The GLADEL multinational Latin American prospective inception cohort of 1,214 patients with systemic lupus erythematosus ethnic and disease heterogeneity among "Hispanics". Medicine. 2004; 83: 1-17.

  10. Juarez M, Misischia R, Alarcon GS. Infections in systemic connective tissue diseases: systemic lupus erythematosus, scleroderma, and polymyositis/dermatomyositis. Rheum Dis Clin North Am. 2003; 29: 163-184.

  11. Cervera R, Khamashta MA, Font J, Sebastiani GD, Gil A, Lavilla P et al. Morbidity and mortality in systemic lupus erythematosus during a 5-year period. A multicenter prospective study of 1,000 patients. European working party on systemic lupus erythematosus. Medicine (Baltimore). 1999; 78: 167-175.

  12. Ramos-Casals M. Viruses and lupus: the viral hypothesis. Lupus. 2008; 17: 163-165.

  13. Danza A, Ruiz IG. Infection risk in systemic lupus eryhtematosus patiens: susceptibility factors and preventive strategies. Lupus. 2013; 12: 1286-1294.

  14. Úcar AE, Rivera GN. Comorbilidad en lupus eritematoso sistémico. Reumatol Clin. 2008; 4 (Supl. 1): S17-S21.

  15. Yewdall V, Cameron JS, Nathan AW. Systemic lupus erythematosus and IgA deficiency. J Clin Lab Immunol. 1983; 10: 13-18.

  16. Falagas ME, Manta KG et al. Infection-related morbility and mortality in patients with connective tissue diseases: a systemic review. Clin Rheumtol. 2007; 26 (5): 663-670.

  17. Molinet FE, Reyes LR, Guibert TM. Evaluación de las infecciones en una serie de pacientes con lupus eritematoso sistémico y artritis reumatoide. Generalidades. Revista Cubana de Reumatología. 2008; 10: 11-12.

  18. Sciascia S et al. Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers. Autoimmunity Reviews. 2012; 12: 157-163.

  19. Kang I, Park SH. Infectious complications in SLE after immunosuppressive therapies. Curr Opin Rheumatol. 2003; 15: 528-534.

  20. Doria A et al. Infections as triggers and complications of systemic lupus erythematosus. Autoimmunity Revieus. 2008; 8: 24-28.

  21. Ramires GL, Velásquez JF, Grand P, Alfonzo BC, Jaimes F. Asociación de actividad lúpica y el riesgo de infección nosocomial en pacientes de un hospital universitario en Medellín: estudio prospectivo 2001-2004. Revista Colombiana de Reumatología. 2007; 14 (14):177-186.

  22. Ramos A. Infecciones en el paciente inmunodeficiente. ¿Qué papel tienen los fármacos? Reumatol Clin. 2008; 4 (Supl. 3): 1-6.

  23. Muñoz GC et al. Complicaciones infecciosas en lupus eritematoso sistémico. Rev Colomb Reumatol. 2013; 20 (3): 141-147.

  24. Mandell G, Bennett J, Dolin R. Principles and practice of infectious disease. 6th ed. Philadelphia: Elsevier; 2005. pp. 6-14.

  25. Sullivan KM, Witherspoon RP, Storb R, Weiden P, Flournoy N, Dahlberg S et al. Prednisone and azathioprine compared with prednisone and placebo for treatment of chronic graft-v-host disease: prognostic influence of prolonged thrombocytopenia after allogeneic marrow transplantation. Blood. 1988; 72: 546-554.

  26. Cupps TR, Edgar LC, Fauci AS. Suppression of human B lymphocyte function by cyclophosphamide. J Immunol. 1982; 128: 2453-2457.

  27. Ginzler E, Diamond H, Kaplan D, Weiner M, Schlesinger M, Seleznick M. Computer analysis of factors influencing frequency of infection in systemic lupus erythematosus. Arthritis Rheum. 1978; 21: 37-44.

  28. Sfikakis P, Boletis J, Tsokos G. Rituximab anti-B cell therapy in systemic lupus erythematosus: pointing to the future. Curr Opin Rheumatol. 2005; 17: 550-557.

  29. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004; 38: 1261-1265.

  30. Fedor ME, Rubinstein A. Effects of long-term low-dose corticosteroid therapy on humoral immunity. Ann Allergy Asthma Immunol. 2006; 97: 113-116.

  31. Trager J, Ward MM. Mortality and causes of death in systemic lupus erythematosus. Curr Opin Rheumatol. 2001; 13: 345-351.

  32. Enberg GM et al. Infections in patients with systemic lupus erythematosus. Rev Méd Chile. 2009; 137: 1367-1374.

  33. Gil A, Lavilla P. Infección y lupus eritematoso sistémico. Cap. 31. En: Font J, Khamashta M, Vilardel M. Lupus eritematoso sistémico. Barcelona: España; 1995.

  34. Yewdall V, Cameron JS, Nathan AW. Systemic lupus erythematosus and IgA deficiency. J Clin Lab Immunol. 1983; 10: 13-18.




2020     |     www.medigraphic.com